Ojima F, Nakamura H, Ebihara M, Shoji T, Tomike H, Nakagawa Y
Department of Pharmacy, Yamagata University Hospital, Yamagata 990-9585, Japan.
Yakugaku Zasshi. 2001 Jan;121(1):79-84. doi: 10.1248/yakushi.121.79.
To determine the prescription characteristics of beta-agonist metered-dose inhalers (MDI), we retrospectively investigated all prescriptions containing one of five types of beta-agonist MDIs available at Yamagata University Hospital in 1997, as well as patients' characteristics. The total number of asthmatic patients was 225 (age, 11-79, mean, 47.2) in 1997. Fenoterol MDI was prescribed to patients who visited the hospital at regular periods and had more severe asthma. Isoprenaline MDI also was not prescribed for first-time patients. Patients who were prescribed tulobuterol MDI had mild or moderate asthma and some of them were only occasional or first-time visitors. Salbutamol and procaterol MDIs were also prescribed for first-time patients; however, tulobuterol MDI was the most frequently prescribed for first-time patients. Patients prescribed fenoterol and isoprenaline MDIs had adequate knowledge of proper asthma management, because sufficient information had been provided about the use of MDIs in the past. Patients prescribed tulobuterol MDI should be provided with detailed instructions because they had little knowledge of handling MDIs and self-management of asthma as many of them were first or intermittent visitors. Patients prescribed salbutamol or procaterol MDIs should be evaluated regarding their past medications and some of them should be instructed regarding the use of the MDI. Although these clinical aspects might be applicable only to our hospital, the same or other prescription patterns will be found in other hospitals and/or by other physicians. Adequate instructions to individual patients who are prescribed a particular beta-agonist MDI should be provided by the medical staff, especially to outpatients, to reduce hospitalization and death from asthma.
为确定β受体激动剂定量吸入器(MDI)的处方特征,我们回顾性调查了1997年山形大学医院开具的含有五种β受体激动剂MDI之一的所有处方以及患者特征。1997年哮喘患者总数为225例(年龄11 - 79岁,平均47.2岁)。非诺特罗MDI用于定期就诊且哮喘病情较重的患者。异丙肾上腺素MDI也未用于初诊患者。使用妥洛特罗MDI的患者哮喘病情为轻度或中度,其中一些只是偶尔就诊或初诊患者。沙丁胺醇和丙卡特罗MDI也用于初诊患者;然而,妥洛特罗MDI是初诊患者中最常开具的。使用非诺特罗和异丙肾上腺素MDI的患者对哮喘的正确管理有足够的了解,因为过去已提供了关于MDI使用的充分信息。使用妥洛特罗MDI的患者应给予详细指导,因为他们对MDI的使用和哮喘自我管理了解甚少,其中许多是初诊或间歇性就诊患者。使用沙丁胺醇或丙卡特罗MDI的患者应评估其既往用药情况,部分患者应给予MDI使用指导。尽管这些临床情况可能仅适用于我们医院,但其他医院和/或其他医生可能会发现相同或其他的处方模式。医务人员应向开具特定β受体激动剂MDI的个体患者,尤其是门诊患者,提供充分指导,以减少哮喘导致的住院和死亡。